Page 47 of 212
Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
Yu RZ, Collins JW, Hall S, Ackermann EJ, Geary RS, Monia BP, Henry SP, Wang Y. Nucleic Acid Ther. 2020 Apr 15. PubMed
April 30, 2020
Reverse Transcription Quantitative Polymerase Chain Reaction Methods to Support Pharmacokinetics and Drug Mechanism of Action to Advance Development of RNA Interference Therapeutics
Castellanos-Rizaldos E, Brown CR, Dennin S, Kim J, Gupta S, Najarian D, Gu Y, Aluri K, Enders J, Brown K, Xu Y. Nucleic Acid Ther. 2020 Mar 23. PubMed
Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration
Goel V, Gosselin NH, Jomphe C, Zhang X, Marier JF, Robbie GJ. Nucleic Acid Ther. 2020 Mar 12. PubMed
Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
Obici L, Berk JL, González-Duarte A, Coelho T, Gillmore J, Schmidt HH, Schilling M, Yamashita T, Labeyrie C, Brannagan TH 3rd, Ajroud-Driss S, Gorevic P, Kristen AV, Franklin J, Chen J, Sweetser MT, Wang JJ, Adams D. Amyloid. 2020 Mar …
MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, phase I trial
Sarker D, Plummer R, Meyer T, Sodergren M, Basu B, Chee CE, Huang KW, Palmer DH, Ma YT, Evans TRJ, Spalding DR, Pai M, Sharma R, Pinato DJ, Spicer J, Hunter S, Kwatra V, Nicholls JP, Collin D, Nutbrown R, …
Page 47 of 212
Page 47 of 212
Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
Yu RZ, Collins JW, Hall S, Ackermann EJ, Geary RS, Monia BP, Henry SP, Wang Y. Nucleic Acid Ther. 2020 Apr 15. PubMed
Reverse Transcription Quantitative Polymerase Chain Reaction Methods to Support Pharmacokinetics and Drug Mechanism of Action to Advance Development of RNA Interference Therapeutics
Castellanos-Rizaldos E, Brown CR, Dennin S, Kim J, Gupta S, Najarian D, Gu Y, Aluri K, Enders J, Brown K, Xu Y. Nucleic Acid Ther. 2020 Mar 23. PubMed
Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration
Goel V, Gosselin NH, Jomphe C, Zhang X, Marier JF, Robbie GJ. Nucleic Acid Ther. 2020 Mar 12. PubMed
Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
Obici L, Berk JL, González-Duarte A, Coelho T, Gillmore J, Schmidt HH, Schilling M, Yamashita T, Labeyrie C, Brannagan TH 3rd, Ajroud-Driss S, Gorevic P, Kristen AV, Franklin J, Chen J, Sweetser MT, Wang JJ, Adams D. Amyloid. 2020 Mar …
MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, phase I trial
Sarker D, Plummer R, Meyer T, Sodergren M, Basu B, Chee CE, Huang KW, Palmer DH, Ma YT, Evans TRJ, Spalding DR, Pai M, Sharma R, Pinato DJ, Spicer J, Hunter S, Kwatra V, Nicholls JP, Collin D, Nutbrown R, …
Page 47 of 212
